Abstract
The neurogenetic prototypic disease on which we chose to test our gene therapy strategy is Canavan disease (CD). CD is an autosomal recessive leukodystrophy associated with spongiform degeneration of the brain. At present the disease is uniformly fatal in affected probands. CD is characterized by mutations in the aspartoacylase (ASPA) gene, resulting in loss of enzyme activity. In this review, recent evidence is summarized on the etiology and possible treatments for CD. In particular, we discuss two gene delivery systems representing recent advances in both viral and liposome technology: a novel cationic liposome-polymer-DNA (LPD) complex, DCChol/DOPE- protamine, as well as recombinant adeno-associated virus (AAV) vectors.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 487-492 |
| Number of pages | 6 |
| Journal | Current Opinion in Molecular Therapeutics |
| Volume | 1 |
| Issue number | 4 |
| State | Published - 1999 |
| Externally published | Yes |
Bibliographical note
Funding Information:This research work has been fully funded by MHRD and AICTE, Govt. of India vide sanction no. 15EDMER005.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS